Table 1 Patient characteristics
Characteristic | Total, n (%) | The group of apatinib combined with SOX regimen in conversion treatment, n (%) | The group of SOX regimen in conversion treatment, n (%) | P value |
|---|---|---|---|---|
Patients, N (%) | 50 | 21 | 29 | |
Age (year) median (range) | 64(50–76) | 64(50–72) | 64(51–76) | 0.496 |
Sex | 0.759 | |||
Male | 31(62.0) | 12(57.1) | 19(65.5) | |
Female | 19(38.0) | 9(42.9) | 10(47.6) | |
ECOG performance status | 0.693 | |||
0 | 29(58.0) | 11(52.4) | 18(85.7) | |
1 | 21(42.0) | 10(47.6) | 11(52.4) | |
Location | 0.603 | |||
Upper | 15(30.0) | 5(23.8) | 10(47.6) | |
Middle | 20(40.0) | 10(47.6) | 10(47.6) | |
Lower | 15(30.0) | 6(28.6) | 9(31.0) | |
Borrmann type | 0.624 | |||
I | 0(0.0) | 0(0.0) | 0(0.0) | |
II | 16(32.0) | 7(33.3) | 9(31.0) | |
III | 27(54.0) | 10(47.6) | 17(58.6) | |
IV | 7(14.0) | 4(19.0) | 3(10.3) | |
Tumor depth | 0.801 | |||
T2 | 0(0.0) | 0(0.0) | 0(0.0) | |
T3 | 26(52.0) | 12(57.1) | 14(48.3) | |
T4a | 6(12.0) | 2(9.5) | 4(13.8) | |
T4b | 18(36.0) | 7(33.3) | 11(52.4) | |
Nodal stage | 0.979 | |||
N1 | 0(0.0) | 0(0.0) | 0(0.0) | |
N2 | 13(26.0) | 6(28.6) | 7(24.1) | |
N3 | 37(74.0) | 15(71.4) | 22(75.9) | |
Peritoneal metastasis | 0.849 | |||
No (P0) | 46(92.0) | 19(90.5) | 27(93.1) | |
Yes (P1) | 4(8.0) | 2(9.5) | 2(6.9) | |
Hepatic metastasis | 0.913 | |||
No (H0) | 42(84.0) | 17(81.0) | 25(86.2) | |
Yes (H1) | 8(16.0) | 4(19.0) | 4(13.8) | |
Ovarian metastasis | 0.613 | |||
No (O0) | 50(100.0) | 21(100.0) | 29(100.0) | |
Yes (O1) | 0(0.0) | 0 | 0(0.0) | |
Clinical Stage | 0.821 | |||
II | 21(42.0) | 8(38.1) | 13(44.8) | |
IVa | 19(38.0) | 8(38.1) | 11(37.9) | |
IVb | 10(20.0) | 5(23.8) | 5(17.2) | |
Peritoneal cytology | 0.849 | |||
Negative | 46(92.0) | 19(90.5) | 27(93.1) | |
Positive | 4(8.0) | 2(9.5) | 2(6.9) | |
No. of non−curative factors | 0.893 | |||
1 | 34(68.0) | 14(66.7) | 20(69.0) | |
v2 | 16(32.0) | 7(33.3) | 9(31.0) | |
Type of gastrectomy | 0.902 | |||
Subtotal | 11(22.0) | 5(23.8) | 6(20.7) | |
Total | 22(44.0) | 11(52.4) | 11(37.9) | |
Postoperative chemotherapy | ||||
Yes | 33(66.0) | 16(76.2) | 17(58.6) | 0.492 |
No | 0(0.0) | 0(0.0) | 0(0.0) |